Cantor Fitzgerald maintained a Hold rating on Ligand Pharma (NASDAQ: LGND) with a price target of $44.00. Analyst Irina Rivkind ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Momentum Movers

Summer Street Adjusts Model, Lifts PT on Ligand (LGND) to $79 Following Q4 NumbersFebruary 12, 2014 9:27 AM Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts AheadFebruary 12, 2014 7:23 AM Ligand Pharma (LGND) Tops Q4 EPS by 16c; Issues Light Q1 OutlookFebruary 11, 2014 8:32 AM